Why CSL shares are rebounding today after falling to an 8- ...
CSL shares recover slightly after hitting an 8-year low as analysts highlight a potential upside from current levels.
www.fool.com.auHere’s the latest I can summarize from recent reporting on CSL Limited (ASX: CSL) and its share price decline.
Core update
Recent price levels and context
Notable events affecting sentiment
What to watch next
If you’d like, I can pull the latest specific price points (current level, intraday moves) and summarize the most recent earnings or guidance notes from CSL and major brokers, then present a concise charted snapshot. I can also tailor a short “watch list” of CSL-related factors for your portfolio.
Would you like me to fetch the latest numbers and create a quick chart of CSL’s price trend over the past 12–24 months? If you have a preferred time window or a broker’s note to focus on, tell me and I’ll align to that.
CSL shares recover slightly after hitting an 8-year low as analysts highlight a potential upside from current levels.
www.fool.com.auCSL shares (ASX:CSL) struck a fresh multi-year low at A$125.78, capping a 49.91% decline over twelve months as repeated guidance cuts and margin pressures continue to erode confidence in what was once Australia's most valuable healthcare stock. The CSL share price closed at their lowest level in nearly 10 years, extending a relentless stair-step decline
thebull.com.auAll the latest CSL (ASX:CSL) share price movements, news, expert commentary and investing advice from The Motley Fool Australia.
www.fool.com.auCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.comThe ASX closed lower as CSL plunged after a profit downgrade, while rising Middle East tensions pressured investor sentiment.
azzet.comCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.comCSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
investors.csl.comCSL shares (ASX: CSL) extended a brutal 12-month selloff, briefly touching A$122.48 before closing higher at A$124.41 on Tuesday, with the price touching it's lowest price levels since 2017 and capping a 50% decline that has stunned long-term holders of what was once Australia's most reliable healthcare compounder. In a potentially interesting twist, the latest
thebull.com.au